1. Home
  2. MIRM vs DNUT Comparison

MIRM vs DNUT Comparison

Compare MIRM & DNUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • DNUT
  • Stock Information
  • Founded
  • MIRM 2018
  • DNUT 1937
  • Country
  • MIRM United States
  • DNUT United States
  • Employees
  • MIRM N/A
  • DNUT N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • DNUT Food Chains
  • Sector
  • MIRM Health Care
  • DNUT Consumer Staples
  • Exchange
  • MIRM Nasdaq
  • DNUT Nasdaq
  • Market Cap
  • MIRM 1.9B
  • DNUT 1.9B
  • IPO Year
  • MIRM 2019
  • DNUT 2021
  • Fundamental
  • Price
  • MIRM $44.50
  • DNUT $10.89
  • Analyst Decision
  • MIRM Strong Buy
  • DNUT Buy
  • Analyst Count
  • MIRM 13
  • DNUT 9
  • Target Price
  • MIRM $57.00
  • DNUT $15.44
  • AVG Volume (30 Days)
  • MIRM 340.6K
  • DNUT 1.8M
  • Earning Date
  • MIRM 11-12-2024
  • DNUT 11-07-2024
  • Dividend Yield
  • MIRM N/A
  • DNUT 1.29%
  • EPS Growth
  • MIRM N/A
  • DNUT N/A
  • EPS
  • MIRM N/A
  • DNUT 0.16
  • Revenue
  • MIRM $307,028,000.00
  • DNUT $1,712,279,000.00
  • Revenue This Year
  • MIRM $73.07
  • DNUT $1.30
  • Revenue Next Year
  • MIRM $27.98
  • DNUT $6.44
  • P/E Ratio
  • MIRM N/A
  • DNUT $66.14
  • Revenue Growth
  • MIRM 112.14
  • DNUT 4.42
  • 52 Week Low
  • MIRM $23.14
  • DNUT $9.18
  • 52 Week High
  • MIRM $48.89
  • DNUT $17.84
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 65.32
  • DNUT 42.25
  • Support Level
  • MIRM $41.09
  • DNUT $10.85
  • Resistance Level
  • MIRM $48.89
  • DNUT $11.35
  • Average True Range (ATR)
  • MIRM 2.16
  • DNUT 0.48
  • MACD
  • MIRM 0.57
  • DNUT -0.11
  • Stochastic Oscillator
  • MIRM 59.09
  • DNUT 2.45

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S., includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line; International includes operations in the U.K., Ireland, Australia, New Zealand, and Mexico; and Market Development includes franchise operations across the globe, as well as operations in Japan. It derives maximum revenue from U.S. Segment.

Share on Social Networks: